BAYRY stock sentiment todayBayer AG
Sentiment verdict
Gossip first, financials second — COLD at 85% confidence.
Last updated · cached analysis, refreshes periodically
BAYRY
Bayer AGA debt-laden conglomerate trapped in a legal 'litigation trap' with stagnant growth and a slashed dividend.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for BAYRY. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by the 'Monsanto Curse,' with ongoing Roundup (glyphosate) litigation uncertainty and PCB-related liabilities draining cash. Investors are frustrated by the CEO's refusal to break up the company's Crop Science and Pharma divisions, which many believe is necessary to unlock value.
- ·Glyphosate litigation overhang
- ·Calls for structural breakup by activist investors
- ·Pharmaceutical pipeline concerns following Asundexian trial failure
- ·Dividend cut to the legal minimum for debt repayment
Financial
Bayer is struggling with a massive debt load (~€38B) and high interest costs. While the Crop Science division has strong market share, cyclical headwinds in agriculture and patent expirations in the Pharma wing (Xarelto, Eylea) create a precarious fundamental outlook.
- ·Net Debt/EBITDA ratio exceeding 3.5x
- ·Dividend yield significantly reduced to preserve cash
- ·Low P/E ratio (~5x forward) reflects 'value trap' status rather than true value
- ·Negative free cash flow volatility due to legal settlements
Risks
- ·Further adverse jury verdicts in US tort litigation
- ·Failure to replace revenue from top-selling drugs facing patent cliffs
- ·Persistent high leverage limiting R&D investment capability
- ·Softening commodity prices impacting agricultural sales
Peer temperature
How direct competitors stack up against BAYRY right now.
- NEUTRALSYNGSyngenta Group
HOTTER — maintains a cleaner balance sheet and stronger R&D pipeline in seeds without the multi-billion dollar legal overhang.
See full analysis → - NEUTRALBASFYBASF SE
HOTTER — while facing German energy costs, it lacks the existential legal threats and offers a more reliable dividend profile.
See full analysis → - HOTCTVACorteva Inc.
HOTTER — pure-play agricultural focus with higher margins and significant share buybacks unencumbered by pharmaceutical R&D risks.
See full analysis →
- BAYRY+0.7%
- SYNG—
- BASFY+4.6%
- CTVA+11.7%
Analyst price target
Consensus average of 1 analyst · median 15.50
Source: StockAnalysis.com · updated 2026-08-18
AI-generated analysis for informational purposes only. Not financial advice.